Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms-Reference-Cited by-同舟云学术

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms

Published:2017-11-28 Issue:1 Volume:61 Page:169-183
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Doecke James D.¹²,Rembach Alan³,Villemagne Victor L.³⁴,Varghese Shiji³⁵,Rainey-Smith Stephanie⁶,Sarros Shannon³⁵,Evered Lisbeth A.⁷,Fowler Christopher J.³,Pertile Kelly K.³,Rumble Rebecca L.³,Trounson Brett³,Taddei Kevin⁶,Laws Simon M.⁶,Macaulay S. Lance¹,Bush Ashley I.³,Ellis Kathryn A.⁸,Martins Ralph⁶,Ames David⁸,Silbert Brendan⁷,Vanderstichele Hugo⁹,Masters Colin L.³⁵,Darby David G.³,Li Qiao-Xin³⁵,Collins Steven³¹⁰⁵,

Affiliation:

1. CSIRO Health and Biosecurity/Australian e-Health Research Centre, Brisbane, QLD, Australia

2. Cooperative Research Centre for Mental Health, Parkville, VIC, Australia

3. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia

4. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia

5. National Dementia Diagnostics Laboratory, The University of Melbourne, VIC, Australia

6. Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia

7. Department of Anaesthesia and Perioperative Pain Medicine, Centre for Anaesthesia and Cognitive Function, St Vincent’s Hospital, Melbourne, Australia

8. Academic Unit for Psychiatry of Old Age, The University of Melbourne, Melbourne, Australia

9. ADx NeuroSciences, Gent, Belgium

10. Department of Medicine (RMH), The University of Melbourne, Parkville, Australia

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference51 articles.

1. Epidemiological and economic burden of Alzheimer’s disease: A systematic literature review of data across Europe and the United States of America;Takizawa;J Alzheimers Dis,2015

2. Drug development in Alzheimer’s disease: The path to 2025;Cummings;Alzheimers Res Ther,2016

3. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease;Karran;Ann Neurol,2014

4. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study;Villemagne;Lancet Neurol,2013

5. Longitudinal change in CSF Tau and Abeta biomarkersfor up to 48 months in ADNI;Toledo;Acta Neuropathol,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a prediction model of conversion to Alzheimer’s disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project;Diagnostic and Prognostic Research;2024-07-25

2. Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity;Neurology;2024-07-09

3. Development of a prediction model of conversion to Alzheimer’s disease in subjects with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project;2024-01-17

4. Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease;Translational Neurodegeneration;2023-07-12

5. How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer’s disease with standardization of measurements?;Clinical Biochemistry;2023-02